lumicitabine
Small moleculeexperimental
Lumicitabine (ALS-8176) is an antiviral drug which was developed as a treatment for respiratory syncytial virus (RSV) and human metapneumovirus (hMPV). It acts as an RNA polymerase inhibitor. While it showed promise in early clinical trials, poor results in Phase IIb trials led to it being discontinued from development for treatment of RSV. Research continues to determine whether it may be useful for the treatment of diseases caused by other RNA viruses, and it has been found to show activity against Nipah virus. — Wikipedia
Clinical trial activity
14 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
8
Phase 2
6
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2013 (NCT01906164)
Timeline
Indications
Mechanism of action
- Respiratory syncytial virusINHIBITOR
Respiratory syncytial virus inhibitor
- RNA-directed RNA polymerase LINHIBITOR
RNA-directed RNA polymerase L inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CC(C)C(=O)OC[C@@]1(CCl)O[C@@H](n2ccc(N)nc2=O)[C@H](F)[C@@H]1OC(=O)C(C)C- Mol. weight
- 433.86 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Prodrug
Sources
- ChEMBLCHEMBL3417258 ↗
- WikipediaLumicitabine ↗
Also known as
- 4'-chloromethyl-2'-deoxy-3',5'-di-o-isobutyryl-2'-fluorocytidine
- als-008176
- als-008176
- als-008176
- als-8176
- lumicitabine
- lumicitabine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03502694 | Phase 2 | Nov 5, 2018 | Johnson and Johnson |
| NCT03468777 | Phase 1 | Mar 6, 2018 | Johnson and Johnson |
| NCT03441529 | Phase 1 | Feb 9, 2018 | Johnson and Johnson |
| NCT03332459 | Phase 2 | Jan 5, 2018 | Johnson and Johnson |
| NCT03333317 | Phase 2 | Nov 24, 2017 | Janssen Pharmaceutica NV |
| NCT02935673 | Phase 2 | Oct 25, 2016 | Johnson and Johnson |
| NCT02833831 | Phase 1 | Jun 1, 2016 | Alios BioPharma |
| NCT02813460 | Phase 1 | Jun 1, 2016 | Johnson and Johnson |
| NCT02673476 | Phase 2 | Feb 1, 2016 | Alios BioPharma |
| NCT02478333 | Phase 1 | May 1, 2015 | Janssen Pharmaceutica NV, Johnson and Johnson |
| NCT02231671 | Phase 1 | Aug 1, 2014 | Alios BioPharma, Quotient |
| NCT02202356 | Phase 1 | Jul 1, 2014 | Alios BioPharma |
| NCT02094365 | Phase 2 | Mar 1, 2014 | Alios BioPharma, hVIVO Services Limited |
| NCT01906164 | Phase 1 | May 1, 2013 | Alios BioPharma |
Showing 14 of 14 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Johnson and Johnson | For profit | 7 | 7 | 2 | 2015 |
| Alios BioPharma | For profit | 6 | 6 | 2 | 2013 |
| Janssen Pharmaceutica NV | For profit | 2 | 1 | 2 | 2015 |
| hVIVO Services Limited | For profit | 1 | 0 | 1 | 2014 |
| Quotient | For profit | 1 | 0 | 1 | 2014 |
5 organizations
Page 1 / 1